ZA202205546B - Methods for providing continuous therapy against pnag comprising microbes - Google Patents

Methods for providing continuous therapy against pnag comprising microbes

Info

Publication number
ZA202205546B
ZA202205546B ZA2022/05546A ZA202205546A ZA202205546B ZA 202205546 B ZA202205546 B ZA 202205546B ZA 2022/05546 A ZA2022/05546 A ZA 2022/05546A ZA 202205546 A ZA202205546 A ZA 202205546A ZA 202205546 B ZA202205546 B ZA 202205546B
Authority
ZA
South Africa
Prior art keywords
microbes
methods
providing continuous
therapy against
continuous therapy
Prior art date
Application number
ZA2022/05546A
Other languages
English (en)
Inventor
Michael Wyand
Gerald F Swiss
Original Assignee
Alopexx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alopexx Inc filed Critical Alopexx Inc
Publication of ZA202205546B publication Critical patent/ZA202205546B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2022/05546A 2019-11-22 2022-05-19 Methods for providing continuous therapy against pnag comprising microbes ZA202205546B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939331P 2019-11-22 2019-11-22
US202062994130P 2020-03-24 2020-03-24
PCT/US2020/061594 WO2021102320A1 (en) 2019-11-22 2020-11-20 Methods for providing continuous therapy against pnag comprising microbes

Publications (1)

Publication Number Publication Date
ZA202205546B true ZA202205546B (en) 2023-05-31

Family

ID=75980043

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/05546A ZA202205546B (en) 2019-11-22 2022-05-19 Methods for providing continuous therapy against pnag comprising microbes

Country Status (11)

Country Link
US (1) US20230053458A1 (enExample)
EP (1) EP4061411A4 (enExample)
JP (2) JP2023502276A (enExample)
KR (1) KR20220107001A (enExample)
CN (1) CN114845731A (enExample)
AU (1) AU2020386971A1 (enExample)
BR (1) BR112022009924A2 (enExample)
CA (1) CA3162238A1 (enExample)
IL (1) IL293091A (enExample)
WO (1) WO2021102320A1 (enExample)
ZA (1) ZA202205546B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152520A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
US11173199B2 (en) * 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
WO2023173020A1 (en) * 2022-03-11 2023-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody materials and methods targeting microbial polysaccharides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2415358T3 (es) * 2004-04-21 2013-07-25 The Brigham And Women's Hospital, Inc. Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/DPNAG) y procedimientos para el uso de los mismos
CN102159540B (zh) * 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
US20130116423A1 (en) * 2010-04-23 2013-05-09 A. Stewart Campbell Synthetic Oligosaccharides for Staphylococcus Vaccine
WO2012145626A1 (en) * 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
US20150086601A1 (en) * 2012-05-07 2015-03-26 Sanofi Methods for preventing biofilm formation
MX2014013637A (es) * 2012-05-07 2015-02-05 Sanofi Sa Metodos para prevencion de la formacion de biopelicula.
RU2019101166A (ru) * 2012-05-30 2020-03-02 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Композиции полисахаридов и способы применения
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Also Published As

Publication number Publication date
JP2026016535A (ja) 2026-02-03
BR112022009924A2 (pt) 2022-08-09
WO2021102320A1 (en) 2021-05-27
CN114845731A (zh) 2022-08-02
JP2023502276A (ja) 2023-01-23
US20230053458A1 (en) 2023-02-23
CA3162238A1 (en) 2021-05-27
KR20220107001A (ko) 2022-08-01
EP4061411A1 (en) 2022-09-28
IL293091A (en) 2022-07-01
EP4061411A4 (en) 2023-11-29
AU2020386971A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
GB201900702D0 (en) Therapy
ZA202205546B (en) Methods for providing continuous therapy against pnag comprising microbes
GB202113079D0 (en) New therapy
GB202103164D0 (en) Therapy
GB202002639D0 (en) Therapy
GB201918752D0 (en) New therapy
GB201912191D0 (en) New therapy
GB202111035D0 (en) Therapy
GB202108303D0 (en) Therapy
GB201914006D0 (en) Combination Therapy
GB201910473D0 (en) Combination therapy
GB201906864D0 (en) Combination therapy
GB202117706D0 (en) Therapy
GB202109893D0 (en) PeptiBAC therapy
GB202104427D0 (en) Therapy
GB202102211D0 (en) PeptiBAC therapy
GB202019218D0 (en) Therapy
GB202017598D0 (en) Therapy
GB202017554D0 (en) Therapy
GB202015778D0 (en) Therapy
GB202015780D0 (en) Therapy
GB201919036D0 (en) Therapy
GB202013824D0 (en) PeptiBAC therapy
GB202013834D0 (en) PeptiVAX therapy
GB201916983D0 (en) Therapy